Thrivent Financial for Lutherans Decreases Stake in IQVIA Holdings Inc. $IQV

Thrivent Financial for Lutherans lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 10.2% in the fourth quarter, Holdings Channel reports. The fund owned 27,211 shares of the medical research company’s stock after selling 3,096 shares during the quarter. Thrivent Financial for Lutherans’ holdings in IQVIA were worth $6,133,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Boston Partners purchased a new position in IQVIA in the 3rd quarter worth approximately $676,698,000. AQR Capital Management LLC boosted its holdings in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares during the period. Citigroup Inc. boosted its holdings in IQVIA by 108.2% in the 3rd quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after acquiring an additional 475,557 shares during the period. Cantillon Capital Management LLC boosted its holdings in IQVIA by 27.3% in the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock worth $366,002,000 after acquiring an additional 413,256 shares during the period. Finally, Invesco Ltd. boosted its holdings in IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock worth $526,891,000 after acquiring an additional 367,204 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQV stock opened at $171.47 on Thursday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $28.62 billion, a P/E ratio of 21.25, a P/E/G ratio of 1.66 and a beta of 1.18. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The stock’s 50 day simple moving average is $169.85 and its 200 day simple moving average is $198.11.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue was up 8.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has initiated a stock buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities analysts have weighed in on IQV shares. Morgan Stanley set a $225.00 price target on IQVIA in a report on Thursday, May 7th. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price on the stock. UBS Group cut their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Citigroup cut their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and a consensus target price of $225.69.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.